Search PubMed⌕ Search

Biomedical subjects

Zbigniew Stanisław Herman

Publications and source records attributed to Zbigniew Stanisław Herman.

30 records · Page 2Linked to original sources
PubMed2005

[Prostate cancer chemoprevention].

Prostatic cancer is the most common malignancy diagnosed in men. Chemoprevention of prostatic cancer is a relatively new concept and seems to be a very promising strategy for preventing and arresting the development of this neoplasm. There is much evidence that the increased consumption of selenium, vitamins E and D, lycopen, soy and isoflavonoids and low-fat diet reduce the risk of the incidence of prostatic cancer. Similar effect is also exhibited by some drugs including finasteride, non-steroid anti-inflammatory drugs and lipoxygenase inhibitors. In this paper we summarize the results of published epidemiologic and scientific studies, trying to critically evaluate the potential clinical role and mechanism of action of these agents in modern chemoprevention of this cancer.

Carotenoids↗
PubMed2005

[Nephrogenic diabetes insipidus induced by colchicine--a case report].

In some cases diabetes insipidus may be induced by taking medications. In this article we report the case of a 58-year-old man with manifest polyuria induced by colchicine administered because of a gout attack. Interestingly, similar symptoms were observed 6 years earlier after treatment with gentamycin. In the described state of the examined patient early detection of the disease, colchicine withdrawal and temporary amiloride (and indometacin) administration led to a full normalisation of the patient's clinical status. A similar reaction to two different drugs responsible for only a small percentage of iatrogenic diabetes insipidus suggests that some patients may exhibit a general "hypersensitivity" to the development of a drug-induced vasopressin resistance and that patients with the history of iatrogenic diabetes insipidus should not be treated or should be treated cautiously with other drugs known to induce vasopressin-resistant polyuria.

Amiloride↗
PubMed2005

[An unusual clinical presentation of the autoimmune polyendocrine syndrome].

Organ-specific autoimmune endocrine disorders may occur together in autoimmune polyendocrine syndromes (APS). The diverse names given to APS and the underestimation of their real frequency reflect the large number of studies and case reports concerning these patients and heterogeneity in their clinical presentation. In this article we report the case of a 64-year-old man, initially diagnosed with Addison's disease and type 2 diabetes mellitus. Clinical examination, laboratory tests and radiological examination revealed the presence of co-existing Graves' disease and enabled us to classify the type of his diabetes as latent autoimmune diabetes in adults (LADA). Taking into account all his disorders, we assume that our patient suffers from a variant of type 2 APS. In the described state of the examined patient, accurate diagnosis, modification of hitherto treatment and implementation of new treatment strategies not only improved his clinical status but also allowed avoiding unnecessary administration of some drugs. This case illustrates the need for clinical awareness of APS in patients with any diagnosed autoimmune endocrine disorder.

Addison Disease↗
PubMed2005

[Normoaldosterone spironolactone sensitive hypertension--a case report].

We report the case of normoaldosterone spironolactone sensitive hypertension. Patients suffering from this recently identified form of arterial hypertension exhibit clinical symptoms resembling the symptoms of primary aldosteronism. The described disturbances may be misdiagnosed as essential hypertension because plasma aldosterone levels and aldosterone/renin ratio in patients are within the normal ranges. In the described state of the examined female, detection of the disease and implementation of spironolactone treatment not only normalised arterial blood pressure but also allowed to avoid unnecessary administration of many antihypertensive agents.

Aged↗
PubMedDate not supplied

Update on the management of polycystic ovary syndrome.

Polycystic ovary syndrome (PCOS) is a common endocrine disorder that affects 5% to 10% of women in reproductive age. It is the most simply defined as the association of hyperandrogenism (diagnosed clinically and/or biochemically) with chronic anovulation in the absence of specific ovarian, adrenal and pituitary gland diseases. Recent studies have revealed that PCOS is associated with hyperinsulinemia and insulin resistance. Both of them have been shown to play a substantial role in the increased risk of the cardiovascular events. The new data concerning the pathogenesis and management of PCOS have changed its treatment strategy. The management of PCOS is complex and includes lifestyle modification combined with dietary-induced weight loss, oral contraceptives, clomiphene citrate, gonadotropins, antiandrogens and insulin-sensitizing agents. Women with PCOS, diagnosed and managed properly, can benefit from the reduction or even reversal of the reproductive and metabolic morbidities and from the reduction of the risk factors for cardiovascular disorders. In this article, we describe all these treatment options. Although both standard and novel therapies are discussed, this review focuses on the progress made in the recent years.

Female↗